Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iNeo-Vac-R01 with Sintilimab, Bevacizumab and TACE in Advanced HCC
NCT06995105Phase 2Recruiting
- Sponsor
- Zhejiang University
- Start
- Apr 2025
- Primary completion
- Apr 2027
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of iNeo-Vac-R01 in hepatocellular carcinoma (HCC), sponsored by Zhejiang University. Started Apr 2025; status: recruiting.
02
Drugs
iNeo-Vac-R01
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06995105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06995105.